News on Tarceva

Roche's Tarceva helps lung cancer patients

2011-06-03T10:00:09Z

ZURICH (Reuters) - Roche Holding AG's cancer drug Tarceva nearly doubles the time patients with a distinct type of lung cancer live without their disease getting worse, a late-stage trial showed on Friday.

The data will be presented at this year's <...

Roche’s Tarceva Proves Effective in China Lung Cancer Trial

2010-11-02T12:15:24Z

...

Tarceva May Improve Survival From Lung Cancer

2010-10-11T20:56:03Z

...

Roche drugs point to personalized lung cancer care

2010-10-09T05:00:05Z

MILAN (Reuters) - Roche's experimental drug MetMab and its established product Tarceva showed impressive results in lung cancer trials on Saturday, highlighting how treating the disease is becoming much more focused.

Cancer experts meeting Milan said personalized t...

Pfizer's Failure Provides Clarity for ArQule

2010-09-11T18:11:24Z

...

FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer

2010-10-25T14:29:36Z

...

Matching Tumor Types to Drugs Boosts Lung Cancer Outcomes

2010-10-25T14:29:36Z

...

Pfizer Ends Study on Potential Lung Cancer Drug

2010-10-25T11:27:08Z

...

Pfizer ends study on potential lung cancer drug

2010-03-11T15:30:17Z

Pfizer ends study on potential lung cancer drug, committee says it won't meet treatment goal

Pfizer Inc. said Thursday it discontinued a late-stage study of the drug candidate figitumumab in patients with late-stage lung cancer, citing a lack of effectiveness.

The company said an independent monitoring committee recommended stopping the study. It concluded that figitumumab in conjunction with science journal Nature.

The new type could add powerfully to a small family of drugs called epidermal growth factor receptor (EPFR) inhibitors, say its finders.

It tackles mutations in a specific form of lung tumour that often becomes hardened to frontline tre...

Lung Cancer Alliance Disappointed With Food and Drug Administration Committee Recommendation

2010-10-24T15:17:15Z

...

Lilly to Benefit from OSI Rejection

2010-10-22T13:01:33Z

...

Screening for Gene Mutations in Lung Cancer and Response to Treatment

2010-10-22T07:35:55Z

...

New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy

2010-10-24T09:15:39Z

...

The Little Biotech That Could

2010-10-24T09:30:48Z

...

OSI: Tarceva Approved as Maintenance Treatment for Lung Cancer

2010-10-22T07:17:51Z

...

OSI: TARCEVA AS MAINTENANCE TREATMENT FOR NON-SMALL-CELL LUNG CANCER

2010-10-22T07:17:40Z

...

FDA Calendar Updates: BioMarin, OSI, Roche, Abraxis, Johnson & Johnson

2010-10-22T07:17:48Z

...

Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer

2010-10-24T09:14:25Z

...

Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer

2010-10-23T23:04:40Z

...

Results Presented at AACR Differentiate STA-9090 in Hsp90 Inhibitor Class and Show Activity in Erlotinib (Tarceva)-resistant Lung Cancer Models

2010-10-23T23:04:36Z

...

Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer

2010-10-23T19:22:04Z

...

China Medical Develops Predictor for Biologic Cancer Drug Success

2010-10-21T09:12:50Z

...

Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer

2010-10-23T16:02:28Z

...

Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

2010-10-23T16:01:14Z

...

Lung cancer drug is banned in England because of its cost - but will be available to Scots

2010-10-19T14:19:43Z

...